by swvision | Dec 21, 2018 | ROP & Telemedicine
Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity. Abstract IMPORTANCE: The present strategy to identify infants needing treatment for retinopathy of prematurity (ROP) requires repeated examinations of at-risk...
by swvision | Dec 21, 2018 | ROP & Ranibizumab
Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity Abstract A former 24-week-old premature infant was treated with intravitreal ranibizumab (Lucentis; Genentech, South San Francisco, CA) in one eye and conventional laser in...
by swvision | Dec 21, 2018 | ROP & Ranibizumab
Histopathologic Characterization of the Expression of Vascular Endothelial Growth Factor in a Case of Retinopathy of Prematurity Treated With Ranibizumab Abstract PURPOSE: To characterize the expression of vascular endothelial growth factor (VEGF) in a patient with...
by swvision | Dec 20, 2018 | ROP Management
Management of Infantile and Childhood Retinopathies: Optimized Pediatric Pars Planta Vitrectomy Sclerotomy Nomogram Purpose To develop a nomogram based on age and disease type for sclerotomy placement in pars plana vitrectomy for infants and children with congenital...
by swvision | Dec 20, 2018 | Micro-Premature Infants, ROP Management
The severity and associated comorbidities of retinopathy of prematurity among micro-premature infants with birth weights less than 750 grams. OBJECTIVES: To evaluate the characteristics and comorbidities associated with ROP in micro-premature infants and their...
